Instil Bio (TIL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

TIL · Stock Price

USD 8.03-5.65 (-41.30%)

Market Cap: $54.8M

Historical price data

Overview

Instil Bio is a publicly traded biotech focused on sourcing and developing novel therapies in immuno-oncology and cell therapy. Led by a team of seasoned investors and operators with a proven track record of successful biopharma exits, the company employs a strategic holding and development model rather than early-stage discovery. Its value proposition is rooted in the leadership's extensive network and scientific acumen to evaluate and advance external opportunities toward clinical validation and commercial partnerships.

OncologyImmunology

Technology Platform

Instil Bio's core capability is a strategic asset development platform, leveraging the leadership team's extensive network and expertise in deal sourcing, scientific due diligence, and clinical development strategy within immuno-oncology and cell therapy, rather than a proprietary technological engine.

Pipeline

4

4 drugs in pipeline

Drug	Indication	Stage
ITIL-168	Advanced Cutaneous Melanoma	Phase 2
AXN-2510	Solid Tumor, Adult	Phase 1
ITIL-306	Epithelial Ovarian Cancer	Phase 1
ITIL-168	Cervical Cancer	Phase 1

Opportunities

The primary opportunity lies in leveraging a proven leadership team to acquire and strategically develop an undervalued asset in the vast immuno-oncology/cell therapy market, creating significant shareholder value through a partnership or acquisition exit.

The capital-efficient, asset-centric model allows for focused resource deployment without the high burn of internal discovery.

Risk Factors

The most significant risk is the complete lack of a disclosed pipeline, making valuation highly speculative.

Additional risks include failure to identify a quality asset, clinical failure of any future acquired program, severe dilution from necessary capital raises, and intense competition for both assets and eventual market share.

Competitive Landscape

Instil Bio competes with other asset acquirers and venture-creation firms for licensing opportunities, and will eventually face direct therapeutic competition from large pharma and biotechs depending on its chosen asset. Its key differentiator is the specific investment and operational track record of its leadership in successful oncology exits.

More companies in Cell & Gene Therapy →More companies in United States →